Ottobock has reported a strong first half of 2026, with core revenue rising 7.7% to €818.5 million, supported by continued growth in prosthetics, neuro-orthotics and its expanding Patient Care business.
The German human bionics group also recorded a sharp increase in profitability, with underlying core EBITDA growing 18.1% to €207 million. Its underlying core EBITDA margin improved from 23.1% to 25.3%.
For India’s prosthetics and orthotics sector, the results provide another important signal that global demand for advanced O&P technologies remains robust, particularly in prosthetics, neuro-rehabilitation and digitally enabled clinical care.
Ottobock said its first-half performance reflected strong organic growth alongside continued investment in new technologies, acquisitions and clinical services.
Prosthetics and neuro-orthotics lead B2B growth
One of the most important figures for CPOs is the performance of Ottobock’s Products & Components division.
Revenue in the division increased from €428.5 million in H1 2025 to €461.6 million in H1 2026, representing reported growth of 7.7%.
Organic growth was even stronger at 8.7%, with Ottobock specifically highlighting positive momentum in prosthetics and neuro-orthotics.
This division includes the company’s core prosthetic and orthotic components alongside digital O&P solutions, exoskeletons and other mobility technologies.
For the Indian market, the continuing strength of this business is significant.
India is seeing growing interest in advanced prosthetic knees, feet, digital socket workflows, neuro-orthotic technologies and more sophisticated rehabilitation systems. At the same time, the country has a very large population requiring affordable prosthetic and orthotic care.
The challenge for manufacturers and clinics remains balancing access and affordability with growing demand for higher-function technology.
EMEA posts double-digit reported growth
Ottobock’s strongest regional performance came from Europe, the Middle East and Africa, where revenue increased 12.2% to €610.2 million.
Organic growth in the region reached 9%, supported by double-digit organic growth in its B2B business as well as expansion of its Patient Care operations.
While India is reported separately within Ottobock’s broader international structure and the company does not provide detailed India-specific figures in the announcement, strong growth in large neighbouring and emerging markets is relevant to Indian CPOs and distributors.
The same global trends affecting Europe and the Middle East are increasingly visible in India: greater adoption of microprocessor-controlled prosthetics, more digital fabrication, rising interest in neuro-rehabilitation and growing investment in private rehabilitation services.
Patient Care network reaches more than 420 centres
Ottobock is also continuing to expand its direct clinical footprint.
Revenue from its Patient Care division rose 7.6% to €356.9 million, compared with €331.7 million in the first half of 2025.
The company now operates a network of more than 420 O&P patient-care centres worldwide.
That expansion is strategically important for independent prosthetic and orthotic clinics.
Historically, major O&P manufacturers primarily supplied components and technologies to independent CPOs. Increasingly, large international groups are also building or acquiring clinical networks and establishing direct relationships with patients.
This creates a more vertically integrated business model where the same organisation can participate in product development, manufacturing, software, clinical provision and long-term patient care.
For India’s still highly fragmented O&P sector, it offers a glimpse of how the international market is evolving.
Ottobock broadens its neuro-rehabilitation portfolio
Another important element of Ottobock’s first-half activity is its continued expansion beyond conventional prosthetics and orthotics.
The company invested in Blue Arbor Technologies, which develops human-machine interface technology, while also agreeing to acquire Spanish company Fesia Technology, a specialist in Functional Electrical Stimulation.
These developments show how the boundaries between prosthetics, orthotics, rehabilitation robotics and neurological rehabilitation are becoming increasingly blurred.
For Indian CPOs, physiatrists, physiotherapists and rehabilitation centres, this could become an important growth area.
A future orthotic prescription may increasingly involve combinations of traditional bracing, electrical stimulation, sensor-based gait assessment and digital rehabilitation tools.
This evolution could also create new clinical roles and business opportunities for O&P professionals willing to develop expertise beyond conventional fabrication.
Portfolio becomes more focused
At the same time, Ottobock has continued to restructure its portfolio.
The company confirmed the sale of its Human Mobility wheelchair business, indicating that it is concentrating resources around areas more closely aligned with human bionics, prosthetics, orthotics and neurological rehabilitation.
That strategic direction is worth watching.
Large O&P companies are increasingly deciding where they want to compete and investing heavily in technologies that directly influence human movement, rehabilitation and physical function.
For India, this could accelerate the arrival of technologies such as functional electrical stimulation, intelligent orthoses, wearable robotics and more advanced digital prosthetic systems.
Profits grow faster than revenue
Ottobock’s profitability also improved faster than its sales.
Underlying net income rose 23.9% to €85.1 million, compared with €68.7 million in the first half of 2025.
Reported net income increased to €67.3 million from €28 million.
The company attributed the improvement partly to higher organic revenue, stronger sales in its Products & Components business, better operating efficiency and cost discipline.
For the O&P sector, these figures show that advanced rehabilitation technology is not simply a clinical growth area. It is increasingly becoming an attractive and scalable commercial market.
Full-year outlook upgraded
Following the first-half performance, Ottobock has strengthened its full-year expectations.
The company now forecasts organic core revenue growth of between 6% and 8%, compared with previous guidance of 5% to 8%.
It also expects its underlying core EBITDA margin to exceed 27%, improving on earlier guidance of more than 26.5%.
The upgraded outlook suggests that Ottobock expects continued demand for prosthetic, orthotic and neuro-rehabilitation technologies through the remainder of 2026.
What the results mean for India’s O&P sector
For Bharat CPO readers, the bigger story is not simply Ottobock’s revenue growth.
The results illustrate the direction in which the global O&P sector is moving.
Prosthetic and orthotic component manufacturers are increasingly becoming broader rehabilitation technology companies. Their portfolios are expanding into neurotechnology, digital workflows, functional electrical stimulation, exoskeletons and direct patient-care services.
India is likely to experience many of the same changes.
The country has a significant population requiring prosthetic and orthotic services, a growing private healthcare sector and an expanding network of rehabilitation hospitals, universities and specialist clinics.
At the same time, digital fabrication, 3D printing and advanced prosthetic technologies are becoming more accessible.
This creates opportunities for Indian CPOs—but also makes continuous professional and technological development increasingly important.
Clinics that previously differentiated themselves primarily through fabrication skills may increasingly need capabilities in digital scanning, CAD, gait analysis, advanced component selection and neurological rehabilitation.
Ottobock’s H1 2026 results show that investors and major manufacturers continue to see strong long-term potential in prosthetics and orthotics.
For India’s O&P profession, the message is clear: the sector is growing, but it is also becoming more technologically sophisticated and commercially integrated.
- Ottobock – H1 2026 financial results
- Ottobock Investor Relations – Results and Reports
- Ottobock India
- Bharat CPO